Martin Moehlen, MD
Gastroenterology · Portland, MENPI 1104006279
Payments from drug & device makers
Across 637 payments — averaging $2252.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$511K
- Merck$299K
- Gilead$192K
- Intercept Pharmaceuticals, Inc.$172K
- AbbVie$130K
- Madrigal Pharmaceuticals$42K
- plus $88K from 15 others
Across 1 payment — averaging $77.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$78
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 18 | $510,962 |
| Merck | 57 | $299,357 |
| Gilead | 211 | $192,315 |
| Intercept Pharmaceuticals, Inc. | 171 | $172,046 |
| AbbVie(2 entities) | 61 | $129,670 |
| Madrigal Pharmaceuticals | 31 | $41,781 |
| Bausch Health US, LLC | 1 | $27,750 |
| Novartis | 4 | $23,300 |
| AstraZeneca | 2 | $12,351 |
| Ipsen Biopharmaceuticals, Inc | 8 | $12,175 |
| Shionogi Inc | 8 | $8,115 |
| Exelixis Inc. | 7 | $3,126 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $668 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $283 |
| Johnson & Johnson | 14 | $228 |
| Eisai Inc. | 8 | $118 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $118 |
| Mallinckrodt Hospital Products Inc. | 4 | $67 |
| Bristol Myers Squibb | 3 | $65 |
| Bayer | 3 | $46 |
| Dova Pharmaceuticals | 1 | $16 |
How this compares
$1,434,555 in reported general payments places this provider in the 95th percentile of 68 gastroenterology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Portland
- Douglas HowellPortland$1.2M
- Noemi BaffyPortland$65K
- Fernando CalmetPortland$51K
- Marina KimPortland$33K
- Andrew HsuPortland$4K
- Eric VecchioPortland$3K
- Andreas StefanPortland$2K
- Daniil RolshudPortland$1K
- Matthew GrunwaldPortland$805
- Cristina RutherfordPortland$670
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.